A new study has found that some people with obstructive sleep apnea and obesity may benefit much more from the GLP-1 medication tirzepatide than others.
Researchers say the findings could help doctors better predict which patients are likely to see the strongest improvements in their sleep apnea symptoms and who may still need additional treatments.
The research was presented at the 2026 American Thoracic Society International Conference and focused on patients with obstructive sleep apnea, often called OSA, who also had obesity.
Obstructive sleep apnea is a common condition where breathing repeatedly stops or becomes blocked during sleep. These pauses in breathing happen because the airway collapses or becomes blocked, reducing airflow to the lungs.
People with sleep apnea often snore loudly, wake up tired, experience daytime fatigue, and may struggle with memory, concentration, or mood problems.
Sleep apnea can also raise the risk of high blood pressure, heart disease, stroke, diabetes, and accidents caused by daytime sleepiness. Obesity is one of the biggest risk factors because extra tissue around the neck and airway can make breathing more difficult during sleep.
In recent years, GLP-1 medications such as tirzepatide have gained attention for helping people lose significant amounts of weight. Tirzepatide affects hormones involved in appetite and blood sugar control, helping people feel fuller and eat less.
The drug has already shown benefits for obesity and type 2 diabetes, and newer research suggests it may also improve sleep apnea symptoms in some patients.
However, doctors noticed that not everyone responds equally well.
The new study aimed to understand why some patients improve dramatically while others experience more modest benefits.
The research team, led by Dr. Scott Sands from Brigham and Women’s Hospital and Harvard Medical School, performed a secondary analysis using data from an earlier clinical trial involving tirzepatide treatment in people with obesity and sleep apnea.
The scientists identified what they called a “strong response endotype,” meaning a subgroup of patients who experienced especially large improvements in sleep apnea severity.
Patients in this group showed nearly twice the level of improvement compared with other patients receiving the same treatment.
The researchers found several common characteristics among these strong responders. They tended to be younger and had milder obesity compared to others in the study.
More importantly, they also shared specific breathing and airway characteristics linked to the biological causes of their sleep apnea.
One key factor involved greater upper-airway collapsibility. This means their airways were more likely to collapse during sleep. While this may sound negative, researchers found these patients responded especially well to tirzepatide treatment.
The strong responders also showed greater “loop gain,” which refers to instability in the body’s breathing control system. In people with high loop gain, breathing can become overly sensitive and unstable during sleep, increasing the chances of repeated breathing disruptions.
Another feature was that these patients tended to wake up more easily when airflow became blocked.
Initially, the researchers were surprised that high loop gain predicted better treatment response. However, further analysis suggested tirzepatide may help improve both airway collapse and breathing instability at the same time.
This finding suggests the medication may affect more than just body weight.
According to Dr. Sands, the results could help doctors give patients more realistic expectations about treatment outcomes.
At present, doctors can usually only describe the average response seen in clinical studies. On average, tirzepatide reduces sleep apnea severity by about half compared to placebo treatment.
But these new findings suggest some patients may experience much larger improvements while others may still require additional therapies such as CPAP machines or other treatments.
The researchers hope this approach will eventually allow more personalized sleep apnea care.
Instead of using a one-size-fits-all approach, doctors may one day identify which patients are most likely to benefit strongly from medications like tirzepatide based on their airway characteristics, breathing patterns, age, and obesity severity.
The study also highlights the growing interest in combining weight-loss medicine with sleep medicine. As obesity rates continue rising worldwide, sleep apnea cases are also increasing rapidly.
Traditional sleep apnea treatment often involves continuous positive airway pressure machines, known as CPAP machines, which keep airways open during sleep. While effective, some patients find CPAP difficult or uncomfortable to use consistently.
Medications that improve both weight loss and sleep apnea may therefore provide important new treatment options in the future.
The researchers plan to continue studying sleep apnea outcomes across different weight-loss therapies, including both medications and non-drug approaches.
If you care about sleep health, please read studies about foods that help people sleep better, and Keto diet could improve cognitive function in people with sleep loss.
For more health information, please see recent studies about the natural supplements for sound sleep, and how your diet can improve sleep quality.
Source: Brigham and Women’s Hospital.
